Core Insights - Ocugen, Inc. is actively participating in key industry conferences to showcase its advancements in gene therapies for blindness diseases and aims to achieve three Biologics License Applications (BLAs) within the next three years [2][5] Group 1: Conference Participation - Ocugen's executive leadership will present at the 2025 Cell & Gene Meeting on the Mesa, Chardan's 9th Annual Genetic Medicines Conference, and the 2025 Maxim Growth Summit [1][4] - Dr. Shankar Musunuri, Chairman and CEO, will engage in discussions about the company's progress and potential partnerships during these events [2][4] - Specific presentation details include: - Cell & Gene Meeting on the Mesa: October 6, 2025, at 4 p.m. MST in Phoenix, AZ [3] - Chardan's 9th Annual Genetic Medicines Conference: October 21, 2025, from 9:30-10:10 a.m. EDT in New York, NY [3] - 2025 Maxim Growth Summit: October 22, 2025, from 3-4 p.m. EDT in New York, NY [4] Group 2: Company Overview - Ocugen is a biotechnology leader focused on gene therapies for blindness diseases, utilizing a modifier gene therapy platform that addresses complex diseases caused by imbalances in multiple gene networks [5] - The company is developing therapies for inherited retinal diseases, including retinitis pigmentosa, Stargardt disease, and geographic atrophy, which affect millions globally [5]

Core Insights - Ocugen, Inc. is a biotechnology leader focused on gene therapies for blindness diseases, with upcoming participation in key investment conferences [1][2][4] - Dr. Shankar Musunuri, the CEO, will engage in discussions aimed at expanding the company's visibility and investor relations in the biotech sector [2][4] Conference Details - Dr. Musunuri will participate in the H.C. Wainwright 27 Annual Global Investment Conference from September 8-10, 2025, in New York, with a fireside chat scheduled for September 8 at 5 p.m. ET [3] - The company will also be featured in a panel discussion titled "The FDA Gauntlet: Strategies for a Successful Run at Approval" during Biotech on Tap 2025, taking place from September 24-26, 2025, in Munich, with the panel set for September 25 at 3:30 p.m. CET [3] Company Overview - Ocugen's modifier gene therapy platform aims to address significant unmet medical needs for large patient populations suffering from inherited retinal diseases and other blindness conditions, including retinitis pigmentosa and geographic atrophy [4] - The company's approach is gene-agnostic, targeting complex diseases caused by imbalances in multiple gene networks, differentiating it from traditional gene therapies [4]

Company Overview - Ocugen, Inc. is a pioneering biotechnology leader focused on gene therapies for blindness diseases, utilizing a breakthrough modifier gene therapy platform to address significant unmet medical needs for large patient populations [3]. Upcoming Events - Ocugen will host a conference call and live webcast to discuss its first quarter 2025 financial results and provide a business update on May 9, 2025, at 8:30 a.m. ET [1]. - A pre-market earnings announcement will be issued on the same day, with dial-in numbers provided for U.S. and international callers [2]. Product Development - The company is developing programs for inherited retinal diseases and blindness diseases affecting millions globally, including retinitis pigmentosa, Stargardt disease, and geographic atrophy [3].